Hepatitis C Diagnosis and Treatment Market at an All-Time High till 2022 Industry Forecast with F. Hoffmann-La Roche Ltd, BMS, Merck & Co., Etc Players by MRFR Market Research Future published a research report on Global Hepatitis C Diagnosis and Treatment Market provide detailed analysis of the market structure along with forecast for the next 10 years of the various segments and sub-segments of the Hepatitis C Diagnosis & Treatment market Global Hepatitis C Diagnosis and Treatment Market - Overview Hepatitis C is the inflammation of liver caused by infection by hepatitis C virus characterized by a host of symptoms such as yellowed eyes and skin due to bilirubin, flulike symptoms which include nausea, vomiting, poor appetite, joint pain, headaches, clay coloured stools etc. According to the World Health Organisation, hepatitis C affects between 130–150 million people globally every year claiming a toll of 700000 lives. Of those who recover about 15-20% develop liver cirrhosis or liver cancer. According to Centres for Disease Control & Prevention, in U.S., liver cancer incidence is increasing at a rapid rate (2.3 % per year overall from 2003 – 2012), second only to thyroid cancer. Moreover, the rate of deaths due to liver cancer is increasing faster than for any other type of cancer. Furthermore, Hepatitis B and C are major contributing factors to liver cancer. According to American Cancer Society, Worldwide, the most common risk factor for liver cancer is chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV). These infections lead to cirrhosis of the liver and are responsible for making liver cancer the most common cancer globally. The market for hepatitis C diagnosis & treatment is driven by factors such as increasing prevalence of liver cancer, rise in government subsidy and reimbursement especially in U.S., greater screening especially in developing nations, drug abuse and unsafe sex etc. On the other hand, the market constraining factors are self-imitating nature of the disease in a sizable number of patients, challenge of herbal treatment offered at negligible prices especially in developing regions, price war between companies such as between Gilead and Merck, rising urbanization and better sanitation etc. Get Sample PDF Illustration @ https://www.marketresearchfuture.com/sample_request/1569 Key Players for Global Hepatitis C Diagnosis and Treatment Market Some of the key players in this market are: F. Hoffmann-La Roche Ltd (Switzerland), BMS (U.S), Merck & Co., Inc (U.S), Vertex Pharmaceuticals Incorporated (U.S) and others. Global Hepatitis C Diagnosis and Treatment Market-Competitive Analysis Hoffmann-La Roche Ltd (Switzerland), BMS (U.S), Merck & Co., Inc (U.S), Vertex Pharmaceuticals Incorporated (U.S), Gilead sciences Inc (U.S.)., Abbvie Inc (U.S.), Johnson & Johnson (U.S.), Glaxosmithkline plc (U.K), Novartis AG (Switzerland), BristolMyers Squibb (U.S.) are some of the prominent players at the forefront of competition in the Global Hepatitis C Diagnosis and Treatment Market and are profiled in MRFR Analysis.
Hepatitis C Diagnosis and Treatment Market at an All-Time High till 2022 Industry Forecast with F. H
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.